Trending Topic

Breast Cancer
29 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Endocrine therapy (ET) has changed the natural history of hormone receptor-positive (HR+) breast cancer (BC) and is the cornerstone of the treatment of HR+ BC. There are several ETs approved for the treatment of BC, including selective oestrogen receptor modulators (SERMs; tamoxifen), aromatase inhibitors (AIs; anastrazole, letrozole and exemestane) and selective oestrogen receptor degraders (SERDs; fulvestrant […]

Jennifer C King, ASCO 2018 – Lung Cancer Alliance supporting unmet needs in NSCLC

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 7th 2018

Jennifer C King, PhD, Director of Science and Research at the Lung Cancer Alliance, Washington, DC, talks to us about unmet needs in non-small cell lung cancer and the role Lung Cancer Alliance plays in supporting patients and research.

1. Could you tell us a little about the services provided by the Lung Cancer Alliance? (0:11)

2. Could you give us a brief overview of the areas of research supported by the Lung Cancer Alliance? (1:02)

3. What do you consider the most important unmet needs in the treatment of non-small cell lung cancer (NSCLC)? (1:40)

4. What research advances in NSCLC therapy have excited you most in the last year? (2:45)

5. What do you expect to be the highlights of this year’s ASCO conference? (4:00)

Speaker disclosures: Jennifer C King has nothing to disclose in relation to this video interview.

Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup